Day 1
Session 1: Molecular biomarkers and novel imaging in APC
- State of the art on molecular characterization in advanced prostate cancer (Pritchard)
- Clinical utility of molecular markers (De Bono)
- Which men need genetic counselling and/or testing? (Eeles)
- Advantages and pitfalls of PSMA PET/CT in APC imaging
Advantages (Fanti)
Pitfalls (Davis)
Session 2: Node-positive prostate cancer (N1 but M0) Chairs
- How to treat men with newly diagnosed cN1 cM0:
Surgery (Murphy)
Radiation therapy (Roach)
Systemic therapy (James) - Synthesis – How best to treat cN1 prostate cancer (Fizazi)
- How to treat men with pathological node positive (pN1, cM0) prostate cancer? (Bossi)
Session 3: PSA recurrence after radical local therapy and oligometastatic prostate cancer
- Management of men with PSA recurrence after radical local radiation therapy (Feng)
- Management of men with PSA recurrence or persistence after prostatectomy (Evans)
- Oligometastatic prostate cancer – Definitions and concepts (Reiter)
- Treatment of de novo (synchronous) oligometastatic prostate cancer (Morris)
- Treatment of oligorecurrent (metachronous) prostate cancer after local therapy (Ost)
- Treatment of oligometastatic and oligoprogressive CRPC) (Small)
Session 4: Regional care (demographic and environmental factors
- Ethnicity and prognosis (Logothetis)
- Pharmaco-ethnicity and impact on treatment (Poon)
- Report and lessons learned from the consensus conference for developing countries (Maluf)
- Disparities in prostate cancer management in the U.S. (Morgans)
- The ageing population: Oncogeriatric assessment and treatment considerations (O’Sullivan)
Day 2
Extra Session: Movember
- Outcomes Research – Ironman project (Morgans, Davis)
Session 5: Management of metastatic castration-sensitive/naive prostate cancer
- Testosterone measurement – Which test and when? (Gleave)
- Local treatment of the primary tumour (RT) in the metastatic situation (Bristow)
- Local treatment of the primary tumour (surgery) in the metastatic situation (Steuber)
- Which systemic therapy for which patient with newly diagnosed metastatic prostate cancer? (Sweeney)
- Addition of AR pathway inhibitors vs. docetaxel: Statisticians’ perspective (Sydes)
- Synthesis – Optimal treatment of men with newly diagnosed metastatic prostate cancer (Clarke)
- Follow-up on ADT alone vs. ADT “plus” (Oh)
Session 6: Management of castration-resistant prostate cancer (CRPC)
- Definition and overview of treatment options in nmCRPC (Scher)
- Debate: Treatment of nmCRPC
Pros (Hussain)
Cons (Higano) - First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor (Taplin)
- Subgroup analysis of mCRPC clinical trials (Halabi)
- PSMA targeted therapies (Hofman)
- Immunotherapy (Drake)
- PARP inhibition (Chi)
- Neuroendocrine spectrum: Diagnosis and treatment (Efstathiou)
Session 7: Side effects of treatment and their management
- Management of sexuality and incontinence issues in APC (Van Oort)
- Management of hot flushes (Frydenberg)
- Management of metabolic changes (Shore)
- Management of fatigue, cognition/dementia (Ryan)
- Optimal steroid use with abiraterone (Attard)
Session 8: Bone and bone metastases
- Prevention/Treatment of osteoporosis (Saad)
- Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC
Only for very select men with CRPC and bone metastases (Parker)
For the majority of men with CRPC and bone metastases (Tombal)
Synthesis – Best use of antiresorptive therapy in CRPC (Smith) - Radium-223 and bone health agents (Sartor)
- The flare phenomenon in bone-metastatic APC (Padhan)i
Session 9: The future of APC management
- Wishes from a patient’s perspective (Millman)
- In locally advanced prostate cancer (Briganti)
- In oligometastatic prostate cancer (Beltran)
- In polymetastatic prostate cancer (Oh)
- In imaging (Fanti)
- In biomarkers (Rubin)
- Global access to treatments (Fizazi)